Biomea Fusion files preliminary prospectus for stock and pre-funded warrant offering
The company filed a shelf take-down on September 22, 2026, with Konik Capital Partners underwriting, to fund diabetes and obesity drug development.
Biomea Fusion, Inc. filed a preliminary prospectus supplement dated September 22, 2026, describing a planned offering of common stock and, for certain investors, pre-funded warrants, under an existing $300.0 million shelf registration. The company has engaged Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC, to act as underwriter.1 Biomea's common stock trades on Nasdaq under the symbol "BMEA," and the last reported sale price on September 21, 2026 was $1.71 per share.1
Biomea describes itself as a clinical-stage company developing small molecule medicines for diabetes and obesity. Its lead candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin.1 As of the filing date, icovamenib is in two ongoing Phase II trials, COVALENT-211 and COVALENT-212, in type 2 diabetes.1
The company reported 52-week results from its Phase II COVALENT-111 trial in October 2025, and reported topline results from its type 1 diabetes trial, COVALENT-112, in April 2026.1 In August 2026, Biomea said enrollment was complete in COVALENT-211, a randomized, double-blind trial of 64 participants across 18 sites testing a 100 mg daily dose of icovamenib for 12 weeks, followed by a 40-week off-treatment period to assess durability of glycemic control, with a primary endpoint at Week 26 and follow-up through Week 52.1
In September 2025, Biomea announced FDA clearance of the investigational new drug application for BMF-650, an oral GLP-1 receptor agonist candidate, and its Phase I trial in obese volunteers is ongoing, with topline results expected in October 2026.1
The company said it intends to use net proceeds from the offering, along with existing cash, to complete Phase II development of icovamenib in type 2 and type 1 diabetes, engage the FDA on registrational studies, and continue clinical development of BMF-650.1 In connection with the offering, the company and its directors and executive officers have entered into 60-day lock-up agreements.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.